A 28-year-old man with newly diagnosed Graves' disease presents with severe thyrotoxicosis, palpitations, and tremor. He has no plans for pregnancy. Which is the first-line antithyroid drug for his management?

Explanation

## First-Line Antithyroid Agent in Non-Pregnant Hyperthyroidism **Key Point:** Methimazole is the preferred first-line antithyroid drug in non-pregnant patients with Graves' disease due to superior tolerability, longer half-life, and once-daily dosing. PTU is reserved for pregnancy or PTU-specific indications. ### Why Methimazole is Preferred in Non-Pregnant Patients **High-Yield:** In non-pregnant adults, methimazole offers: 1. **Longer half-life (4–6 hours)** → once or twice daily dosing vs. PTU's thrice-daily requirement 2. **Better tolerability** → lower incidence of hepatotoxicity (PTU carries risk of severe hepatitis) 3. **Faster symptom relief** when combined with β-blockers 4. **No teratogenic risk** in non-pregnant individuals ### Comparison of Thionamide Agents | Feature | Methimazole | PTU | Carbimazole | Potassium Perchlorate | |---------|-------------|-----|-------------|----------------------| | **Mechanism** | Inhibits TPO | Inhibits TPO + blocks T₄→T₃ | Prodrug of methimazole | Inhibits iodine uptake | | **Half-life** | 4–6 hours | 1–2 hours | 8–10 hours | 24 hours | | **Dosing** | 1–2× daily | 3× daily | 1–2× daily | 2–4× daily | | **Hepatotoxicity** | Mild | Severe (0.1–0.2%) | Mild | Rare | | **Agranulocytosis** | 0.3–0.5% | 0.2–0.5% | Similar to MMI | Rare | | **Use in pregnancy** | Contraindicated (1st trimester) | Preferred | Contraindicated | Rarely used | | **First-line (non-pregnant)** | **Yes** | No | No | No | **Clinical Pearl:** The main advantage of PTU—blocking peripheral T₄ → T₃ conversion—becomes less relevant once initial thyroid hormone levels are controlled. In steady-state management, methimazole's superior pharmacokinetics and safety profile dominate. ### Typical Dosing & Titration **Methimazole:** - Initial: 15–30 mg daily (divided into 1–2 doses) - Maintenance: 5–15 mg daily after euthyroid state achieved - Titrate based on TSH and free T₄ levels **PTU (if used):** - Initial: 100–150 mg three times daily - Maintenance: 50–100 mg three times daily ### Role of Other Options - **PTU:** Reserved for pregnancy, first trimester, or patients with methimazole allergy/intolerance. Not first-line in non-pregnant adults. - **Carbimazole:** A prodrug of methimazole (metabolized in vivo). Equivalent efficacy but no additional advantage; rarely used in India. Not first-line. - **Potassium perchlorate:** Inhibits iodine uptake but carries risk of aplastic anemia and nephrotic syndrome. Reserved for rare cases of iodine-induced thyrotoxicosis or severe PTU/methimazole reactions. **Mnemonic:** **MMI (Methimazole) for Most** — Methimazole is the first-line agent for most non-pregnant patients with hyperthyroidism.